Contract SPE2D222D0145
Mylan Pharmaceuticals Inc · Department Of Defense · August 15, 2024
Mylan Pharmaceuticals Inc was awarded a federal contract by Department Of Defense (Defense Logistics Agency) on August 15, 2024 for an undisclosed amount of work in pharmaceutical preparation manufacturing. It was awarded under full and open competition. The contract has been modified 2 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on August 20, 2025. If all options are exercised, the contract could reach $9.55 million.
Contract details
- PIID
- SPE2D222D0145
- Award type
- Indefinite Delivery / Requirements
- Pricing
- Firm Fixed Price
- Set-aside
- No Set Aside Used.
- Competition
- Full And Open Competition
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- First action
- August 15, 2024
- Latest action
- August 20, 2025
Description
4610093699!
Modification timeline
-
August 20, 2025Mod P00008 · Change Order$0
-
April 22, 2025Mod P00007$0
-
August 15, 2024Mod P00006 · Change Order4610093699!MANUFACTURE/DISTRIBUTOR BR-PH$0
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Cardinal Health, Inc. | Department Of Defense | January 1, 2026 | $51 |
| Cardinal Health, Inc. | Department Of Defense | January 1, 2026 | $91 |
| Cardinal Health, Inc. | Department Of Defense | January 1, 2026 | $32 |
| Cardinal Health, Inc. | Department Of Defense | January 1, 2026 | $1.1K |
| Cardinal Health, Inc. | Department Of Defense | January 1, 2026 | $22 |
| Cardinal Health, Inc. | Department Of Defense | December 31, 2025 | $23 |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 1,187 | $4.96B |
| 2 | Merck Sharp & Dohme Llc | 26 | $894.71M |
| 3 | Sanofi Vaccines Us Inc. | 57 | $702.38M |
| 4 | Pfizer Inc | 169 | $541.15M |
| 5 | Glaxosmithkline, Llc | 14 | $505.04M |
| 6 | Phlow Corp. | 1 | $105.27M |
| 7 | Exelan Pharmaceuticals Inc | 76 | $104.30M |
| 8 | Seqirus USA Inc | 47 | $59.15M |
| 9 | Emergent Biosolutions Canada Inc | 2 | $53.73M |
| 10 | Mckesson Specialty Distribution Llc | 1 | $51.05M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract SPE2D222D0145?
Contract SPE2D222D0145 is a federal contract awarded to Mylan Pharmaceuticals Inc by Department Of Defense on August 15, 2024 for an undisclosed amount of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 2 times since the base award.
Who won contract SPE2D222D0145?
Mylan Pharmaceuticals Inc won contract SPE2D222D0145 from Department Of Defense.
How much is contract SPE2D222D0145 worth?
Contract SPE2D222D0145 has obligated $0 to date but carries a potential ceiling of $9.55 million if fully funded and all options are exercised.